These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 7268901)

  • 21. Regulation of the graft-versus-host response by genes in the H-2D and T regions.
    Elkins WL
    Transplant Proc; 1981 Mar; 13(1 Pt 2):1220-2. PubMed ID: 6168070
    [No Abstract]   [Full Text] [Related]  

  • 22. Split tolerance to the MHC class I molecule H-2Dd in animals transgenic for its soluble analog.
    Hunziker RD; Lynch F; Shevach EM; Margulies DH
    Hum Immunol; 1997 Feb; 52(2):82-94. PubMed ID: 9077557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonclassical MHC-I and Japanese encephalitis virus infection: induction of H-2Q4, H-2T23 and H-2T10.
    Abraham S; Yaddanapudi K; Thomas S; Damodaran A; Ramireddy B; Manjunath R
    Virus Res; 2008 May; 133(2):239-49. PubMed ID: 18314211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. H-2Dp transgene alters natural killer cell specificity at the target and effector cell levels. Comparison with an H-2Dd transgene.
    Sentman CL; Olsson-Alheim MY; Lendahl U; Kärre K
    J Immunol; 1996 Apr; 156(7):2423-9. PubMed ID: 8786300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms in the in vivo release of lymphokines. VI. Studies with mice congenic at the H-2 region.
    Neta R; Salvin SB; Shreffler DC
    Transplantation; 1982 Jan; 33(1):102-3. PubMed ID: 7064215
    [No Abstract]   [Full Text] [Related]  

  • 26. Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection.
    Aharoni R; Yussim A; Sela M; Arnon R
    Int Immunopharmacol; 2005 Jan; 5(1):23-32. PubMed ID: 15589456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
    Schirmbeck R; Böhm W; Reimann J
    J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Class I MHC antigens of different subregions induce different IgG subclasses.
    Tartakovsky B; De Baetselier P; Isakov N; Katzav S; Feldman M; Segal S
    J Immunol; 1983 Mar; 130(3):1017-8. PubMed ID: 6822731
    [No Abstract]   [Full Text] [Related]  

  • 29. MHC class I gene organization in > 1.5-Mb YAC contigs from the H2-M region.
    Jones EP; Xiao H; Schultz RA; Flaherty L; Trachtulec Z; Vincek V; Larin Z; Lehrach H; Lindahl KF
    Genomics; 1995 May; 27(1):40-51. PubMed ID: 7665183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired antibody responses in H-2Ab mice.
    Gustavsson S; Hjulström-Chomez S; Lidström BM; Ahlborg N; Andersson R; Heyman B
    J Immunol; 1998 Aug; 161(4):1765-71. PubMed ID: 9712042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptively transferred CD4+ lymphocytes from CD8 -/- mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts.
    Dalloul AH; Chmouzis E; Ngo K; Fung-Leung WP
    J Immunol; 1996 Jun; 156(11):4114-9. PubMed ID: 8666777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4+ T cells.
    Kapessidou Y; Habran C; Buonocore S; Flamand V; Barvais L; Goldman M; Braun MY
    Transplantation; 2006 Aug; 82(4):582-91. PubMed ID: 16958183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation of functional MHC class I-deficient islet cells.
    Osorio RW; Ascher NL; Jaenisch R; Natuzzi ES; Freise CE; Roberts JP; Stock PG
    Transplant Proc; 1993 Feb; 25(1 Pt 2):968-9. PubMed ID: 8442283
    [No Abstract]   [Full Text] [Related]  

  • 34. Reduced diversity of CTLs specific for multiple minor histocompatibility antigens relative to allograft rejection in vivo.
    Nevala WK; Paul C; Wettstein PJ
    J Immunol; 1997 Feb; 158(3):1102-7. PubMed ID: 9013948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Langerhans cells, orthotopic corneal allografts, and direct and indirect pathways of T-cell allorecognition.
    Sano Y; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1422-31. PubMed ID: 10798658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxic T cells play no essential role in acute rejection of orthotopic corneal allografts in mice.
    Yamada J; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 2001 Feb; 42(2):386-92. PubMed ID: 11157871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H-2 allele-specific protection from NK cell lysis in vitro for lymphoblasts but not tumor targets. Protection mediated by alpha 1/alpha 2 domains.
    Sentman CL; Olsson MY; Salcedo M; Höglund P; Lendahl U; Käre K
    J Immunol; 1994 Dec; 153(12):5482-90. PubMed ID: 7989750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The functional basis of minor histocompatibility loci.
    Roopenian DC; Davis AP; Christianson GJ; Mobraaten LE
    J Immunol; 1993 Nov; 151(9):4595-605. PubMed ID: 8409421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fine specificity of class I MHC recognition in islet allografts.
    Ferguson D; Kohli N; Munn SR
    Transplant Proc; 1995 Dec; 27(6):3222. PubMed ID: 8539924
    [No Abstract]   [Full Text] [Related]  

  • 40. Major histocompatibility complex.
    Goust JM
    Immunol Ser; 1993; 58():29-48. PubMed ID: 8424978
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.